Micro Therapeutics, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Cerebral Aneurysm Multi-Center European Onyx (CAMEO) trial treats 99% (122 of 123) of aneurysms successfully, firm reports Feb. 13. Liquid embolic device hit European market in January, following MTI distribution partnership with ev3 International. In the U.S., MTI completed 30% of total case requirements for two Onyx trials as of year-end 2001, with enrollment completion targeted for the third quarter of 2002 (1"The Gray Sheet" Nov. 5, 2001, p. 26). The Irvine, California company's sales increased 54% in 2001 to $8.8 mil. A net loss of $20.1 mil. compares with a loss of $11.8 mil. in 2000...